NYSE:KDMN - Kadmon Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.60
  • Forecasted Upside: 271.13 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$3.40
▼ -0.13 (-3.69%)
1 month | 3 months | 12 months
Get New Kadmon Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KDMN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KDMN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$12.60
▲ +271.13% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Kadmon in the last 3 months. The average price target is $12.60, with a high forecast of $25.00 and a low forecast of $8.00. The average price target represents a 271.13% upside from the last price of $3.40.
Buy
The current consensus among 5 contributing investment analysts is to buy stock in Kadmon.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/6/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/4/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/2/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/31/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/30/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/29/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/27/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2020

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/9/2020Cantor FitzgeraldReiterated RatingOverweightMedium
i
Rating by A. Young at Cantor Fitzgerald
10/1/2020Raymond JamesReiterated RatingBuyMedium
i
Rating by Steven Seedhouse at Raymond James
9/22/2020OppenheimerReiterated RatingBuy$8.00High
i
8/7/2020Raymond JamesBoost Price TargetOutperform$9.00 ➝ $10.00High
i
Rating by Steven Seedhouse at Raymond James
6/28/2020HC WainwrightReiterated RatingBuy$25.00Low
i
Rating by Andrew Fein at HC Wainwright
5/22/2020HC WainwrightReiterated RatingBuy$25.00Low
i
Rating by Andrew Fein at HC Wainwright
5/19/2020Raymond JamesInitiated CoverageOutperform$7.00High
i
5/7/2020OppenheimerReiterated RatingBuy$8.00Medium
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
3/5/2020OppenheimerReiterated RatingBuy$8.00High
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
2/26/2020HC WainwrightReiterated RatingBuy$25.00Low
i
1/10/2020Nomura SecuritiesInitiated CoverageBuy$10.00High
i
11/12/2019Cantor FitzgeraldBoost Price TargetOverweight$8.00 ➝ $10.00High
i
Rating by E. Merle at Cantor Fitzgerald
9/5/2019Cantor FitzgeraldInitiated CoverageOverweight$8.00Low
i
Rating by E. Merle at Cantor Fitzgerald
6/26/2019OppenheimerInitiated CoverageOutperform$6.00High
i
3/12/2019HC WainwrightReiterated RatingBuy$25.00High
i
2/26/2019CitigroupUpgradeNeutral ➝ Buy$2.77Low
i
11/12/2018HC WainwrightReiterated RatingBuy$25.00High
i
Rating by Andrew Fein at HC Wainwright
10/17/2018WBB SecuritiesUpgradeSell ➝ Hold$2.90Medium
i
8/13/2018HC WainwrightSet Price TargetBuy$25.00Medium
i
Rating by Andrew Fein at HC Wainwright
3/9/2018HC WainwrightReiterated RatingBuy$25.00High
i
Rating by A. Fein at HC Wainwright
2/13/2018Piper Jaffray CompaniesReiterated RatingOverweight ➝ Positive$7.00 ➝ $9.00High
i
2/13/2018Jefferies Financial GroupBoost Price TargetPositive ➝ Buy$16.00High
i
12/15/2017HC WainwrightReiterated RatingBuy$25.00Low
i
Rating by A. Fein at HC Wainwright
11/17/2017HC WainwrightReiterated RatingBuy$25.00N/A
i
Rating by A. Fein at HC Wainwright
10/9/2017WBB SecuritiesDowngradeHold ➝ Sell$3.00N/A
i
8/2/2017Piper Jaffray CompaniesSet Price TargetBuy$7.00Medium
i
Rating by Edward Tenthoff at Piper Jaffray Companies
7/14/2017Piper Jaffray CompaniesReiterated RatingBuy$7.00Medium
i
Rating by Edward Tenthoff at Piper Jaffray Companies
6/26/2017HC WainwrightReiterated RatingBuy$25.00High
i
3/27/2017CitigroupLower Price TargetNeutral$6.00 ➝ $4.00High
i
3/23/2017Piper Jaffray CompaniesReiterated RatingOverweight$36.10 ➝ $23.00Low
i
Rating by Edward Tenthoff at Piper Jaffray Companies
3/16/2017WBB SecuritiesUpgradeSell ➝ Hold$3.25Medium
i
3/14/2017Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$7.00High
i
2/1/2017HC WainwrightReiterated RatingBuy$25.00N/A
i
11/21/2016JMP SecuritiesReiterated RatingBuyN/A
i
Rating by michael king at JMP Securities
11/10/2016Jefferies Financial GroupReiterated RatingBuy$12.00 ➝ $10.00N/A
i
8/22/2016HC WainwrightReiterated RatingBuyN/A
i
Rating by A. Fein at HC Wainwright
8/22/2016JMP SecuritiesInitiated CoverageOutperform$16.00N/A
i
8/22/2016Jefferies Financial GroupInitiated CoverageBuy$12.00 ➝ $12.00N/A
i
8/22/2016HC WainwrightInitiated CoverageBuy$25.00N/A
i
8/22/2016CitigroupInitiated CoverageNeutral$12.00N/A
i
8/1/2016WBB SecuritiesInitiated CoverageSell$7.50N/A
i
(Data available from 10/27/2015 forward)
Kadmon logo
Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include KD025, an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical trial for the treatment of chronic graft-versus-host and fibrotic diseases; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; ribavirin, a nucleoside Inhibitor to treat hepatitis; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. The company was founded in 2010 and is headquartered in New York, New York.
Read More

Today's Range

Now: $3.40
$3.32
$3.58

50 Day Range

MA: $4.03
$3.42
$4.51

52 Week Range

Now: $3.40
$2.30
$5.50

Volume

1,303,916 shs

Average Volume

2,291,181 shs

Market Capitalization

$581.01 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.56